Increased preoperative levels of plasma fibrinogen and d dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 7, 2014, Pages 1031-1040

  Erdem, Selcuk ^a   Amasyali, Akin Soner ^a   Aytac, Omer ^a   Onem, Kadir ^a   Issever, Halim ^a   Sanli, Oner ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

D dimer; Fibrinogen; Renal cell carcinoma

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; D DIMER; FIBRINOGEN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; TUMOR MARKER;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KRUSKAL WALLIS TEST; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANK SUM TEST; RECEIVER OPERATING CHARACTERISTIC; STUDENT T TEST; AGED; BLOOD; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84927573964     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.03.013     Document Type: Article

References (44)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Bensalah K., Pantuck A.J., Crepel M., et al. Prognostic variables to predict cancer-related death in incidental renal tumours. BJU Int 2008, 102:1376-1380.
3. Kyoda Y., Kobayashi K., Hirobe M., et al. Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment. Int J Clin Oncol 2014, 19:146-151.
4. Tsimafeyeu I.V., Demidov L.V., Madzhuga A.V., Somonova O.V., Yelizarova A.L. Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma. J Exp Clin Cancer Res 2009, 28:30.
5. Rickles F.R., Patierno S., Fernandez P.M. Tissue factor, thrombin, and cancer. Chest 2003, 124:58S-68S.
6. Versteeg H.H., Peppelenbosch M.P., Spek C.A. Tissue factor signal transduction in angiogenesis. Carcinogenesis 2003, 24:1009-1013.
7. Wojtukiewicz M.Z., Zacharski L.R., Memoli V.A., et al. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990, 10:579-582.
8. Palumbo J.S., Kombrinck K.W., Drew A.F., et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000, 96:3302-3309.
9. Palumbo J.S., Potter J.M., Kaplan L.S., Talmage K., Jackson D.G., Degen J.L. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002, 62:6966-6972.
10. Staton C.A., Brown N.J., Lewis C.E. The role of fibrinogen and related fragments in tumour angiogenesis and metastasis. Expert Opin Biol Ther 2003, 3:1105-1120.
11. Xiao B., Ma L.L., Zhang S.D., et al. Correlation between coagulation function, tumor stage and metastasis in patients with renal cell carcinoma: a retrospective study. Chin Med J (Engl) 2011, 124:1205-1208.
12. Du J., Zheng J.H., Chen X.S., et al. High preoperative plasma fibrinogen is an independent predictor of distant metastasis and poor prognosis inrenal cell carcinoma. Int J Clin Oncol 2013, 18:517-523.
13. Pichler M., Hutterer G.C., Stojakovic T., Mannweiler S., Pummer K., Zigeuner R. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 2013, 109:1123-1129.
14. Arpaia G., Carpenedo M., Verga M., et al. d-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis 2009, 20:170-175.
15. Harrison K.A., Haire W.D., Pappas A.A., et al. Plasma d-dimer: a useful tool for evaluating suspected pulmonary embolus. J Nucl Med 1993, 34:896-898.
16. Dirix L.Y., Salgado R., Weytjens R., et al. Plasma fibrin d-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002, 86:389-395.
17. Yamamoto M., Yoshinaga K., Matsuyama A., et al. Plasma d-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer. Oncology 2012, 83:10-15.
18. Zhang P.P., Sun J.W., Wang X.Y., Liu X.M., Li K. Preoperative plasma d-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism. Eur J Surg Oncol 2013, 39:951-956.
19. Diao D., Zhu K., Wang Z., et al. Prognostic value of the d-dimer test in oesophageal cancer during the perioperative period. J Surg Oncol 2013 Jul, 108:34-41.
20. Furie B., Furie B.C. The molecular basis of blood coagulation. Cell 1988, 53:505-518.
21. Shoji M., Hancock W.W., Abe K., et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998, 152:399-411.
22. Belting M., Ahamed J., Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005, 25:1545-1550.
23. Mueller B.M., Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998, 101:1372-1378.
24. Bjork I., Olson S.T. Anti-thrombin. A bloody important serpin. AdvExp Med Biol 1997, 425:17-33.
25. O'Reilly M.S., Pirie-Shepherd S., Lane W.S., Folkman J. Anti-angiogenic activity of the cleaved conformation of the serpin anti-thrombin. Science 1999, 285:1926-1928.
26. Larsson H., Sjoblom T., Dixelius J., et al. Anti-angiogenic effects of latent anti-thrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000, 60:6723-6729.
27. AJCC Staging Manual, Edge SB, Byrd DR, Comptom CC et al. editors. 7th ed Philadelphia: Springer 2009.
28. Sahni A., Francis C.W. Vascular endothelial growth factor binds tofibrinogenand fibrin and stimulates endothelial cell proliferation. Blood 2000, 96:3772-3778.
29. Dvorak H.F., Nagy J.A., Berse B., et al. Vascular permeability factor,fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci 1992, 667:101-111.
30. Hembrough T.A., Swartz G.M., Papathanassiu A., et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003, 63:2997-3000.
31. Verheul H.M., van Erp K., Homs M.Y., et al. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology 2010, 75:608-614.
32. Nieswandt B., Hafner M., Echtenacher B., Mannel D.N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999, 59:1295-1300.
33. Yamashita H., Kitayama J., Kanno N., Yatomi Y., Nagawa H. Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 2006, 6:147.
34. Tang L., Liu K., Wang J., Wang C., Zhao P., Liu J. High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer. J Surg Oncol 2010, 102:428-432.
35. Takeuchi H., Ikeuchi S., Kitagawa Y., et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol 2007, 22:2222-2227.
36. Guo Q., Zhang B., Dong X., et al. Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas 2009, 38:e75-e79.
37. Polterauer S., Grimm C., Seebacher V., et al. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 2009, 14:979-985.
38. Seebacher V., Polterauer S., Grimm C., et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer 2010, 102:952-956.
39. Casamassima A., Picciariello M., Quaranta M., et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 2005, 173:52-55.
40. Kattan M.W., Reuter V., Motzer R.J., et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001, 166:63-67.
41. Frank I., Blute M.L., Cheville J.C., et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002, 168:2395-2400.
42. Cindolo L., de la Taille A., Messina G., et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 2003, 92:901-905.
43. Raj G.V., Thompson R.H., Leibovich B.C., et al. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol 2008, 179:2146-2151. [discussion 2151].
44. Karakiewicz P.I., Suardi N., Capitanio U., et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 2009, 55:287-295.